An Investigator-initiated, Multicenter, Phase IV, Open-label Study to Evaluate the Biological Basis for Disease Progression in Relapsing-remitting Multiple Sclerosis Patients Treated in Routine Practice With Gilenya for 2 Years

Trial Profile

An Investigator-initiated, Multicenter, Phase IV, Open-label Study to Evaluate the Biological Basis for Disease Progression in Relapsing-remitting Multiple Sclerosis Patients Treated in Routine Practice With Gilenya for 2 Years

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Biomarker; Therapeutic Use
  • Acronyms IGLOO
  • Most Recent Events

    • 02 Oct 2017 Planned number of patients changed from 400 to 100.
    • 02 Oct 2017 Planned End Date changed from 1 Jun 2020 to 1 Feb 2018.
    • 02 Oct 2017 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top